Replies to post #203581 on Biotech Values

[puravida]

Wow. That's unfortunate for cerulean.

Also in the pipeline for 101 is this. Will be interesting to see where it trades tomorrow

In July U.S. Food and Drug Administration (FDA) granted Fast Track designation for Cerulean's lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer.